For patients with DLBCL treated with R‐CHOP, distinct molecular subtypes might benefit from specific novel targeted agents, which has been a cornerstone of certain clinical trials [50, 51]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.